Duo Oncology, founded by oncologists, aims to revolutionize cancer treatment through the development of ultra-small nanoparticles designed to deliver combinations of cancer medicines deep into solid tumors. The company's mission is to enhance the effectiveness of treatments for difficult-to-target tumors, particularly those surrounded by dense stromal tissue. By mimicking the self-assembly of DNA, Duo Oncology creates nanomedicines that can penetrate deeply within tumors and release their therapeutic payloads in response to specific tumor microenvironment conditions.

Notable figures affiliated with Duo Oncology include its founding oncologists who bring extensive clinical expertise to the company's innovative approach. The startup has garnered attention and support from investors interested in cutting-edge cancer therapies. Key achievements include the successful development of their unique nanoparticle technology, which has shown promise in preclinical studies. Duo Oncology's impact lies in its potential to significantly improve outcomes for patients with challenging tumor types, offering new hope in the fight against cancer.